Anavex Life Sciences Reports Fiscal 2023 Year End Financial Results and Provides Business Update

Anavex Life Sciences to Announce Fiscal 2023 Year End Financial Results on Monday, November 27, 2023

Anavex Life Sciences Announces Grant of U.S. Patent Covering Blarcamesine (ANAVEX®2-73)

Anavex Initiates Regulatory Submission of Oral Blarcamesine for Alzheimer’s Disease

Anavex Life Sciences Appoints Senior VP of Regulatory Affairs

Anavex Announces Appointment of Dr Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board

Anavex Life Sciences Reports Fiscal 2023 Third Quarter Financial Results

Anavex Life Sciences Reports Publication of ANAVEX®3-71

Anavex to Announce Fiscal 2023 Third Quarter Financial Results on Tuesday August 8, 2023

Long-term Clinical Study Demonstrates Disease-Modifying Effects of ANAVEX®2-73 for Rett Syndrome

Anavex Life Sciences and Partex Group Announce Strategic Partnership

Anavex Life Sciences Reports Publication in Medical Journal for Continued Commitment to Improve RSBQ

Completion of ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial

Anavex Life Sciences Reports Fiscal 2023 Second Quarter Financial Results

Anavex Life Sciences to Announce Fiscal 2023 Second Quarter Financial Resultson Tuesday May 9, 2023

Anavex Life Sciences Announces Issuance of New U.S. Patent ANAVEX®2-73 (blarcamesine)

ANAVEX®2-73 (Blarcamesine) Shows Clinical Benefit in Long-Term 48Week Phase 2 Extension Study in PDD

Anavex Life Sciences Appoints Former FDA Lead Neurology Statistician as VP Head of Biostatistics

Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial Results

Anavex Life Sciences Announces Exceeding of Enrollment Target for ANAVEX®2-73 (blarcamesine)